36 studies found for:    "Epithelial-myoepithelial carcinoma"
Show Display Options
Rank Status Study
1 Recruiting Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium
Conditions: Ovarian Clear Cell Carcinoma;   Endometrial Clear Cell Carcinoma
Interventions: Drug: Nintedanib;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin (PLD);   Drug: Topotecan;   Drug: Carboplatin;   Drug: Doxorubicin
2 Recruiting A Study of ENMD-2076 in Ovarian Clear Cell Cancers
Condition: Ovarian Clear Cell Carcinoma
Intervention: Drug: ENMD-2076
3 Unknown 
Has Results
Fludeoxyglucose F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Cell Carcinoma;   Cervical Small Cell Carcinoma;   Cervical Squamous Cell Carcinoma;   Endometrial Clear Cell Carcinoma;   Endometrial Papillary Serous Carcinoma;   Stage I Endometrial Carcinoma;   Stage IB Cervical Cancer;   Stage II Endometrial Carcinoma;   Stage IIA Cervical Cancer;   Stage IIB Cervical Cancer;   Stage III Cervical Cancer;   Stage III Endometrial Carcinoma;   Stage IVA Cervical Cancer
Interventions: Radiation: fludeoxyglucose F 18;   Procedure: positron emission tomography;   Procedure: computed tomography;   Drug: ferumoxtran-10;   Procedure: magnetic resonance imaging;   Procedure: diagnostic lymphadenectomy;   Procedure: lymph node biopsy
4 Unknown  Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma
Conditions: Ovarian Cancer;   Adverse Effects
Intervention: Drug: Sunitinib
5 Withdrawn Endometriosis and Frequency of Endometriosis-associated Ovarian Carcinomas (EAOC)
Conditions: Endometrioid Carcinoma;   Clear Cell Carcinoma;   Endometriosis
Intervention:
6 Recruiting A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
Conditions: Ewing Sarcoma;   Gastrointestinal Tumor;   Germ Cell Tumor;   Hepatic Tumor;   Lymphoma;   Wilms Tumor;   Rhabdoid Tumor;   Clear Cell Carcinoma;   Renal Cell Carcinoma;   Melanoma;   Neuroblastoma;   Rhabdomyosarcoma;   Non-rhabdomyosarcoma
Interventions: Drug: alemtuzumab;   Drug: fludarabine;   Drug: sirolimus;   Drug: Busulfan;   Drug: melphalan;   Biological: stem cells
7 Recruiting MEDI4736 Combinations in Metastatic Renal Cell Carcinoma
Conditions: Renal Clear Cell Carcinoma;   Renal Papillary Cell Carcinoma
Interventions: Drug: Savolitinib;   Drug: MEDI4736;   Drug: Tremelimumab
8 Completed
Has Results
Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer
Conditions: Endometrial Adenocarcinoma;   Endometrial Adenosquamous Cell Carcinoma;   Endometrial Clear Cell Carcinoma;   Endometrial Papillary Serous Carcinoma;   Stage I Endometrial Carcinoma;   Stage II Endometrial Carcinoma;   Stage III Endometrial Carcinoma;   Stage IV Endometrial Carcinoma
Interventions: Radiation: intensity-modulated radiation therapy;   Drug: cisplatin;   Biological: bevacizumab;   Drug: carboplatin;   Drug: paclitaxel
9 Completed
Has Results
Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer
Conditions: Endometrial Adenocarcinoma;   Endometrial Adenosquamous Cell Carcinoma;   Endometrial Clear Cell Carcinoma;   Endometrial Papillary Serous Carcinoma;   Recurrent Endometrial Carcinoma;   Stage IIIA Endometrial Carcinoma;   Stage IIIB Endometrial Carcinoma;   Stage IIIC Endometrial Carcinoma;   Stage IVA Endometrial Carcinoma;   Stage IVB Endometrial Carcinoma
Interventions: Drug: temsirolimus;   Other: laboratory biomarker analysis
10 Completed Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer
Conditions: Endometrial Adenoacanthoma;   Endometrial Adenocarcinoma;   Endometrial Adenosquamous Cell Carcinoma;   Endometrial Clear Cell Carcinoma;   Endometrial Papillary Serous Carcinoma;   Recurrent Endometrial Carcinoma
Interventions: Drug: thalidomide;   Other: laboratory biomarker analysis
11 Completed ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer
Conditions: Non-Small-Cell Lung Carcinoma;   Renal Cell Carcinoma;   Pancreatic Cancer
Intervention: Drug: ABR-217620
12 Completed AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib
Condition: Advanced Renal Cell Carcinoma
Interventions: Drug: AMG 386;   Drug: Sorafenib;   Drug: AMG 386 placebo IV
13 Completed
Has Results
Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney
Condition: Kidney Cancer
Interventions: Biological: aldesleukin;   Biological: bevacizumab
14 Suspended Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Fallopian Tube Clear Cell Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis
15 Suspended Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer
Conditions: Endometrial Clear Cell Adenocarcinoma;   Estrogen Receptor Negative;   Ovarian Clear Cell Cystadenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Recurrent Uterine Corpus Carcinoma
Interventions: Drug: Dasatinib;   Other: Laboratory Biomarker Analysis
16 Completed
Has Results
Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer
Conditions: Carcinoma, Renal Cell;   Adenocarcinoma, Renal Cell;   Nephroid Carcinoma,;   Hypernephroid
Interventions: Drug: RAD001(everolimus);   Drug: interferon alfa-2a;   Drug: bevacizumab
17 Completed Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer
Conditions: Ovarian Clear Cell Cystadenocarcinoma;   Stage III Ovarian Cancer;   Stage IV Ovarian Cancer
Interventions: Drug: Carboplatin;   Drug: Docetaxel;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Drug: Temsirolimus
18 Completed Ovarian Clear Cell Adenocarcinoma Review
Condition: [M]Ovarian Cystadenoma or Carcinoma
Intervention:
19 Recruiting Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma
Condition: Renal Cancer
Intervention: Drug: 124IcG250
20 Active, not recruiting Feasibility Study: Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients
Conditions: Ovarian Cancer;   Primary Peritoneal Carcinoma;   Fallopian Tube Cancer
Interventions: Drug: Propranolol;   Drug: Chemotherapy;   Procedure: Surgery;   Behavioral: Questionnaire

   Previous Page Studies Shown (1-20) Next Page (21-36) Show next page of results    Last Page
Indicates status has not been verified in more than two years